INTRODUCTION
Despite decades of research, the cause of fibrosing idiopathic interstitial pneumonias (IIPs), also known as fibrosing interstitial lung diseases (ILDs), has remained elusive. In the past few years, genetic studies of fibrotic IIPs have led to new insights into disease susceptibility and identified novel targets for further investigation.
Idiopathic pulmonary fibrosis (IPF) is the most common of the fibrosing IIPs. IPF is characterized by scarring of the lung parenchyma, leading to peripheral-and basilar-predominant reticular opacities, volume loss with traction bronchiectasis, and honeycombing on high-resolution computed tomography (CT) and the pattern of usual interstitial pneumonia (UIP) on histopathology [1] . The prognosis is poor, with no effective therapies and a median survival time from diagnosis of 3 years [2] .
The etiology of IPF remains unknown, though it has long been observed that specific environmental exposures are associated with the disease [3] [4] [5] [6] . Numerous studies have indicated that there is a genetic basis for pulmonary fibrosis -twin studies and familial aggregation of cases provided the first signs that inherited factors played a role in disease development [7] [8] [9] [10] . For instance, abnormalities in surfactant proteins in particular are strongly implicated in familial pulmonary fibrosis [11] [12] [13] . In addition, pleiotropic genetic disorders such as dyskeratosis congenita [14] and Hermansky-Pudlak syndrome [15] are associated with pulmonary fibrosis. However, these mutations account for a small proportion of the population risk of disease, making further research into the genetic predisposition necessary.
Recent population studies have pointed to numerous additional specific genetic variants that confer significant risk to development of IPF and other fibrosing IIPs [16,17 && ,18 becoming less clear -indeed, recent findings indicate that both sporadic and familial presentations of IPF have similar genetic risk factors [17 && ,21]. In this review, we summarize current knowledge about genetic risk for the development of pulmonary fibrosis with a focus on the most recent findings in the field. Genes implicated in the development of pulmonary fibrosis can be categorized into three main categories, which will create a framework for the discussion: genes implicated in host defense; genes involved in aging and senescence; and genes involved in cell-to-cell adhesion. We conclude by addressing the implications of recent findingsspecifically, that there may be no genetic difference between sporadic and familial cases of IPF, the most common fibrosing IIP.
HOST DEFENSE
Alterations in an individual's host defense mechanisms have been the target of previous research examining genetic predisposition to fibrotic lung disease. For instance, genetic variation in cytokine genes has been implicated in pulmonary fibrosis in prior studies [22] [23] [24] . More recently, genome-wide association studies (GWAS) have further expanded investigators' focus from the alveolar epithelium and the fibroblast to the role of other host defense mechanisms in the pathogenesis of disease.
Mucins
In 2011, Seibold et al. [16] determined through genome-wide linkage analysis and subsequent fine-mapping/sequencing that a single-nucleotide polymorphism (SNP) rs35705950 on the p-terminus of chromosome 11 is strongly associated with IPF and with familial interstitial pneumonia (FIP), as defined by the presence of two or more cases of definite or probable IIP within three generations of a single family. This SNP resides in the promoter region of the MUC5B gene, which codes for an airway mucin that is highly conserved across primate species. Analysis of other loci in the region showed that rs35705950 remained the most significant SNP. The odds ratios (ORs) for disease among those who are heterozygous (GT) and homozygous (TT) for the minor allele at this site were 6.8 and 20.8 for FIP and 9.0 and 21.8, for IPF, respectively, [16] , suggesting a strong influence of the SNP on disease risk. Not only was IPF diagnosis associated with greater than 14-fold increase in expression of MUC5B in lung tissue regardless of genotype, but presence of the minor allele (T) at rs35705950 was associated with a 37.4-fold increase in gene expression among the unaffected individuals [16] . In the normal human lung, MUC5B is found in the cytoplasm of the secretory columnar cells in the bronchi as well as in bronchioles and has been shown to be one of the dominant gel-forming mucins in the distal airway. In the setting of IPF, MUC5B appears in these locations as well as in the honeycomb cysts that characterize the disease [ (Table 1) . Intriguingly, the rs35705950 variant has also been shown in the general population to be associated with subclinical radiographic interstitial lung abnormalities, which may be precursor lesions to clinically evident pulmonary fibrosis [19 && ]. The odds of having definite fibrosis on a CT scan were 6.3 times higher for each copy of the MUC5B variant [19 && ]. Though this polymorphism is strongly associated with both subclinical interstitial lung abnormalities and with pulmonary fibrosis, it is also associated with improved survival in IPF patients, as shown by a retrospective analysis of two independent cohorts, suggesting that genotype may be a marker of prognosis [20 && ]. A remarkable aspect of the MUC5B variant finding is its high frequency, as it is found in approxi- mately ]. Yet the apparent effect size of this common variant is significant [16] . The frequency of the variant in the CEPH population and the relative
KEY POINTS
Recent genetic studies of IIPs have led to new insights into the susceptibility of individuals for IIPs.
This progress provides investigators new targets to understand the pathophysiology of disease, specifically in the areas of host defense, cell-to-cell adhesion, and aging and senescence.
Genetic risk for development of pulmonary fibrosis appears to be similar in familial as well as sporadic forms of the disease.
Further characterization of the genetic risk of developing pulmonary fibrosis will lead to novel approaches to prevent or delay the onset of this devastating disease.
Better understanding of the genetic risk of developing pulmonary fibrosis also points investigators to new potential therapeutic targets.
infrequency of IPF in the general population suggest a significant role for gene-by-gene or gene-byenvironment interactions in the development of disease. Studies of ILD secondary to sarcoidosis and scleroderma have failed to show an association between variant and these other interstitial lung diseases [27 & ,28 & ,29], though other groups have previously found MUC5B variants associated with diffuse panbronchiolitis in Asian populations [30] .
Despite the strength and reproducibility of these findings, the mechanism by which the MUC5B variant leads to increased risk of pulmonary fibrosis remains unknown. Recent findings in murine models indicate that Muc5b is critical in airway response to pathogens [31 && ]. These findings suggest that dysregulation of MUC5B could impair host defense or contribute to poor clearance of inhaled particles and toxins via disordered mucociliary clearance. Alternatively, excess MUC5B may impair the alveolar repair response, leading to disordered signaling between alveolar epithelia and other matrix-producing cells. Further research on the role of MUC5B in lung injury and repair is needed to clarify its potential role in disease pathogenesis.
Inflammatory mediators
Toll-like receptors (TLRs) are transmembrane receptors that recognize structurally conserved molecules derived from microbes. Another recent GWAS confirmed the MUC5B SNP association and identified three SNPs in Toll-interacting protein (TOLLIP) significantly associated with pulmonary fibrosis [18 & ]. These variants, all associated with differential expression of the gene, implicate the innate immune response in IPF pathogenesis. Intriguingly, one TOLLIP variant (rs5743890) was associated with mortality, providing another example in which genotype may predict prognosis [18 & ]. In a smaller study, a specific variant in TLR3 leading to a functional amino acid substitution (L412F) was found to be associated with decreased TLR3 activity in primary fibroblasts from IPF patients. This nonsynonymous mutation was also associated with early mortality and accelerated lung function decline in those carrying the variant [32] . In the case of asbestos-related lung disease, functional polymorphisms (rs35829419) in the NLRP3 gene, whose product is thought to play a role in inflammation and apoptosis, have also been linked to risk of pulmonary fibrosis [33 & ].
AGING AND SENESCENCE
The ability of the alveolar epithelium to respond to stress and injury has also long been a hypothesized to play a role in the pathogenesis of pulmonary fibrosis, especially since so many presumably injurious exposures (e.g. asbestos, cigarette smoking) have been associated with the disease. Prior studies have indicated that the abnormalities in the ability of epithelial cells to divide and replace epithelia could be central to the pathophysiology of the disease [34, 35, 36 & ], and correspondingly, genetic variants in cell cycle genes have been associated with IPF and disease progression [37] .
Telomeres are repetitive nucleotide sequences at the ends of chromosomes that protect genes from being damaged through the normal DNA replication process, and so are critical to maintaining genomic stability and regulating a cell's replicative capacity [38 & ]. Once telomeres shorten past a threshold, they activate a DNA damage response leading to cell death or cell-cycle arrest. Telomerase maintains telomere length by adding nucleotide repeats to the ends of chromosomes during the replication process and is composed of telomerase reverse transcriptase (TERT) and telomerase RNA component (TERC), which serves as a template for elongation. Not only is telomerase activity ubiquitous in cancerous cells, it is also found in cells undergoing injury and repair processes, including fibrogenesis [39] . Sequence variants in genes regulating telomere length have been associated with numerous age-related diseases, including pulmonary fibrosis [38 & ]. Familial pulmonary fibrosis has been linked to shortened telomeres [40] , and to specific TERT and TERC mutations This table summarizes the published literature confirming the association between the rs35705950 minor allele and IPF that was originally described in 2011 by Seibold et al. [16] . IPF, idiopathic pulmonary fibrosis; SNP, single-nucleotide polymorphism.
[ [40] [41] [42] , some of which are inherited in an autosomal dominant fashion and show evidence of genetic anticipation [12, 40] . Interestingly, IPF patients have shortened telomeres even without the presence of known telomerase mutations [43, 44] , suggesting that there may be factors other than previously described mutations that affect telomere length and, by extension, risk of disease. Subsequent studies have found similar associations of TERT mutations with sporadic IPF [45] [46] [47] . TERT mutations have been found in 10-15% of FIP families, but in the majority of FIP patients, the responsible genetic abnormality has not been found [48,49 & ]. However, recently an X-linked mutation in a third telomerase-associated gene, dyskerin (DKC1), has been described in a family with FIP [49 & ]. DKC1 binds to TERC and stabilizes the telomerase complex; as such, this newly described mutation decreases telomerase activity in the affected individuals [49 & ]. The genetic risk for pulmonary fibrosis conferred by variants in TERT and TERC was confirmed by a large GWAS of individuals with fibrotic IIPs that found common variants in the TERC and TERT loci, 3q26 and 5p15, respectively [17 && ]. Telomerase activity was further implicated in this GWAS by the finding that a common variant in OBFC1, a gene implicated in variation of leukocyte telomere length [50] [51] [52] , was also associated with fibrotic IIP [17 && ]. There is mounting evidence that specific variants in genes affecting telomerase activity or telomere length confer risk of pulmonary fibrosis, but the mechanism(s) by which these genetic changes lead to fibrosis remains unclear. Better understanding of the gene's role in the pathophysiology of fibrosis has the potential to direct us to therapeutic targets.
CELL-TO-CELL ADHESION
A third category of genes recently identified as targets for future investigation are those involved in cell-to-cell adhesion. Specifically, variants in desmoplakin (DSP) and dipeptidyl peptidase 9 (DPP9) are associated with fibrotic IIP [17 && ]. In addition, DSP expression in lung tissue varied with the number of copies of the most statistically significant common variant rs2076295 [17 && ], and DSP and DPP9 have been shown in various organs (heart, skin, kidney) to be critical in epithelial integrity [53] [54] [55] .
Desmoplakin is an important component of the desmosome, a transmembrane structure particularly abundant in cells undergoing constant stretch (heart, skin, and airway). As such, DSP may be particularly important in the regions of the lung that experience constant mechanical stress, such as the peripheral and basilar segments-those that are preferentially affected in the IPF patients [56] . Intriguingly, other investigations have illustrated that DSP acts as a tumor suppressor by suppressing the WNT/b-catenin pathway [57] , one that itself has been implicated in the pathogenesis of IPF [58] [59] [60] . Intracellular DSP interacts with cytoskeleton, suggesting a potential means by which environmental and extracellular exposures could lead to changes in intracellular signaling. Investigations into nonsmall cell lung cancer and other neoplasms illustrate that the desmosome is not merely an adhesion structure, but instead is a dynamic part of the epithelial cell that can alter phenotype via intracellular signaling [61] .
IMPLICATIONS OF RECENT FINDINGS
These recent genetic findings in the field of pulmonary fibrosis have broadened the scope of inquiry into the pathogenesis of disease, prompting numerous questions that require further investigation. In the case of the promoter polymorphism in MUC5B, the variant rs35705950 is not only associated with an increased risk of IPF but also with a 2.8-fold increased risk of having interstitial lung abnormalities and a 6.3-fold increased risk of having definite radiographic evidence of pulmonary fibrosis [19 && ]. Yet, those IPF patients with the rs35705950 allele also had improved survival when compared to those without it [20 && ]. These findings have significant clinical implications, specifically in the use of clinical genetic testing and prospective screening for patients deemed at increased risk of disease. A more complete understanding of the genetic risk of pulmonary fibrosis will allow early detection and more accurate prognostication for patients whose clinical course has been considered unpredictable.
Genes and the environment
The frequency with which many of the variants strongly associated with pulmonary fibrosis (e.g. rs35705950 and rs2076295) are found in the general population suggests that though these genetic variants indicate risk for the development of fibrotic lung disease, there are likely environmental factors contributing to risk of disease development, as well. As illustrated by the 2013 Framingham population study, 19% of the population carries the rs35705950 variant, but the incidence of IPF within that population itself is far less than 1% [19 && ].
Epidemiologists have long observed a link between environmental exposures and the development of both familial and sporadic pulmonary fibrosis-specifically, cigarette smoke, farming, livestock exposure, wood dust, metal dust, and stone/ sand [62] [63] [64] . Other occupational exposures such as asbestos, drug exposures such as bleomycin [65, 66] , and iatrogenic exposures such as radiation [67, 68] have been linked to various forms of pulmonary disease, including fibrosis [69] . Future investigation into the role of gene-by-environment interactions will be critical in understanding the roles that genetic variation and environment play in disease pathogenesis.
Familial vs. idiopathic pulmonary fibrosis
The framework under which clinicians and investigators have understood genetic risk and pulmonary fibrosis to date makes a distinction between 'familial' forms of the disease (familial IIP) and 'idiopathic' fibrosing lung diseases (sporadic IIP). Data from the Fingerlin et al. 2013 study [17 && ] illustrates that odds ratios for development of pulmonary fibrosis for each of the significant genetic loci reported are equivalent in familial and sporadic forms of disease (Fig. 1 ). Although we have previously written of familial and sporadic disease as distinct entities, based on such data, from the perspective of genetic risk of developing pulmonary fibrosis, the two conditions appear equivalent.
CONCLUSION
Many fibrotic IIP patients are diagnosed late in the course of their disease, limiting therapeutic options.
Screening family members of affected individuals may prove a means of detecting and treating earlystage disease. As we understand better gene-byenvironment and gene-by-gene interaction in the pathogenesis of fibrosis, we can target patients earlier in their disease course. Furthermore, given initial findings suggesting differential prognosis based on genotype and the overall genetic heterogeneity of fibrotic lung diseases, genetic variants may prove instrumental in redefining fibrotic IIP subtypes. Finally, novel findings regarding genetic risk of disease point us to new investigational and therapeutic targets.
Acknowledgements
None.
Conflicts of interest
There are no conflicts of interest to disclose. S.K.M. is supported by T32 HL007085 (NIH). D.A.S. is supported by R01 HL097163 and P01 HL092870 (NIH). This study found that the MUC5B promoter polymorphism associated with IPF was found to be associated with interstitial lung abnormalities on CT scan in the general population (i.e. persons without diagnosed ILD); this association was most apparent in older subjects, but was not influenced by smoking status. 20. This study confirmed the MUC5B promoter polymorphism's association with IPF. The findings also suggest that lung fibrosis in the context of other diseases such as systemic sclerosis and sarcoidosis are not asscoiated with this variant, highlighting what are likely to be differences in genetic susceptibility to these distinct diseases.
REFERENCES AND RECOMMENDED READING
28.
